Friday, 15 December 2017
Latest news
Main » Aerie Pharmaceuticals, Inc. (AERI) PT Set at $65.00 by Canaccord Genuity

Aerie Pharmaceuticals, Inc. (AERI) PT Set at $65.00 by Canaccord Genuity

12 October 2017

For the week, the stock is performing -3.32%. Its up 28.39% from 2.51M shares previously. With 229,900 avg volume, 0 days are for 3DX INDUSTRIES INCORPORATED (OTCMKTS:DDDX)'s short sellers to cover DDDX's short positions. The SI to Ulta Beauty Incorporated's float is 5.45%. About 801 shares traded. Ulta Beauty Inc (NASDAQ:ULTA) has risen 41.46% since October 10, 2016 and is uptrending.

Aerie Pharmaceuticals, Inc. (AERI) opened the session with a $53.1 price tag, later ranging from $52.7 to $53.5, the range at which the stock has traded at throughout the day. Aerie Pharmaceuticals Inc (NASDAQ:AERI) has risen 180.20% since October 10, 2016 and is uptrending. About 355,187 shares traded. Aerie Pharmaceuticals has $10000 highest and $30 lowest target. It has outperformed by 163.50% the S&P500. The company's market cap is $2.33 billion. The Firm offers cosmetics, fragrance, skin, hair care products and salon services.

Investors sentiment increased to 1.17 in Q2 2017. Its up 0.07, from 0.98 in 2017Q1. Bailard Inc accumulated 34,500 shares.

Institutional investors now hold around $1.82 billion or 99.72% in AERI stock. Ameritas Investment Prtn, a Nebraska-based fund reported 2,451 shares. Next Century Growth Investors Limited Liability Corporation holds 0.7% or 138,084 shares. Alliancebernstein Ltd Partnership holds 0.02% or 377,384 shares in its portfolio.

In the transaction dated February 15, 2017, the great number of shares disposed came courtesy the Director; Duyk Geoffrey M disposed a total of 41,591 shares at an average price of $46.63, amounting to approximately $1,939,388. The stock declined 0.13% or $0.1 reaching $79.44 on the news. Stifel Financial Corporation reported 83,182 shares or 0.02% of all its holdings. University Of Notre Dame Du Lac has invested 1.59% in The Medicines Company (NASDAQ:MDCO). Bremer Association holds 0.16% or 1,927 shares. Benchmark Cap Advisors reported 13,400 shares.

08/17/2017 - Aerie Pharmaceuticals, Inc. had its "buy" rating reiterated by analysts at Canaccord Genuity. Therefore 78% are positive. Finally, HC Wainwright set a $69.00 price target on shares of Aerie Pharmaceuticals and gave the company a "buy" rating in a report on Wednesday, August 2nd. The rating was maintained by Canaccord Genuity on Wednesday, August 16 with "Buy". Also, there are 1 buy, 0 sell and 0 strong sell ratings, collectively assigning a 1.5 average brokerage recommendation. Cantor Fitzgerald reaffirmed an overweight rating and set a $62.00 price objective (up from $56.00) on shares of Aerie Pharmaceuticals in a research report on Thursday, July 20th. Legal & General Group Plc now owns 7,534 shares of the company's stock worth $396,000 after purchasing an additional 519 shares during the period. The firm has "Buy" rating by Needham given on Friday, September 15.

Since May 9, 2017, it had 1 insider purchase, and 1 insider sale for $1.08 million activity. Tracking most recent quarter period, Price to book (P/B) ration is at 10.40 and Price to cash per share ration is at 6.51. $156,182 worth of stock was sold by Halligan Catherine Ann on Thursday, June 1.

Diamondback Energy, Inc. (FANG) Upgraded by Zacks Investment Research to Buy
BidaskClub downgraded Diamondback Energy from a "sell" rating to a "strong sell" rating in a research note on Tuesday, June 20th. As analysts monitor volatile markets in recent weeks they have updated their price targets on shares of Diamondback Energy, Inc.

While taking a look at financials, we can look at a number of key indicators about Aerie Pharmaceuticals, Inc. A beta of less than 1 means that the security will be less volatile than the market. The Company is engaged in the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. It now has negative earnings. The Company's product candidates include Rhopressa (netarsudil ophthalmic solution) 0.02% (Rhopressa), and Roclatan (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% (Roclatan).

Investors sentiment increased to 1.17 in 2017 Q2. Its up 0.21, from 0.96 in 2017Q1. Zacks Investment Research cut shares of Aerie Pharmaceuticals from a "hold" rating to a "sell" rating in a report on Tuesday. 33 funds opened positions while 48 raised stakes. Bank Of Nova Scotia reported 22,300 shares or 0.01% of all its holdings. Mizuho initiated coverage on Aerie Pharmaceuticals in a research report on Wednesday, September 6th. Ameritas Investment Partners Inc. increased its holdings in shares of Aerie Pharmaceuticals by 11.5% during the second quarter.

The stock of Aerie Pharmaceuticals Inc (NASDAQ:AERI) hit a new 52-week high and has $69.23 target or 7.00% above today's $64.70 share price. Meeder Asset Mngmt reported 962 shares.

Aerie Pharmaceuticals (NASDAQ:AERI) last posted its earnings results on Tuesday, August 1st. Colony Gru Lc holds 5,370 shares.

03/30/2017 - Aerie Pharmaceuticals, Inc. had its "market outperform" rating reiterated by analysts at JMP Securities.

The share price of Aerie Pharmaceuticals, Inc. Orbimed Limited owns 1.83 million shares. The stock of Aerie Pharmaceuticals Inc (NASDAQ:AERI) has "Buy" rating given on Wednesday, August 2 by Cowen & Co.

Aerie Pharmaceuticals, Inc. (AERI) PT Set at $65.00 by Canaccord Genuity